Wholesale
Wholesale pricing available
Qualify for automatic discounts at checkout when your order of wholesale eligible items hits a volume threshold.
$2,000+15% off$4,000+20% off$6,000+25% off$10,000+40% offFull wholesale details →
$1,301.50$1,370.00
($260.30 / Item) — Save $68.50 (5% off)
In stock — dispatches within 24h, tracked
GLP-3 RTA [Triple G] 20mg. Used to support weight management, appetite control, reduced food cravings, and metabolic health. Lab tested, discreetly shipped across Canada.
FormatLyophilized Vial
ConcentrationDependent on reconstitution with BAC water
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
Wholesale pricingCost per item by order value
$2,000+15% off$1,106.27per item
$4,000+20% off$1,041.20per item
$6,000+25% off$976.13per item
$10,000+40% off$780.90per item
Estimated prices based on the current product or selected option price. Tiers use your eligible wholesale subtotal before the wholesale discount. Discounts apply automatically in your cart.
Choose an option to see its wholesale prices.
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide-1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s 20mg formulation delivers the second lowest concentration presentation across CSD’s full GLP-3 RTA range as a lyophilized vial, sitting above the 30mg entry point and providing a stepped concentration increase for dose escalation research protocols examining triple incretin receptor co activation across a defined concentration ladder.
The 20mg concentration occupies a specific position in the GLP-3 RTA research series that warrants distinction from the 30mg variant. Where the 30mg format serves as the lowest reference point for initial compound evaluation and baseline pharmacological response characterization, the 20mg format. Being lower in concentration is particularly suited to the earliest stages of dose response mapping where sub threshold and near threshold receptor activation research is the primary variable. This makes the 20mg presentation a valuable tool for researchers establishing the full lower bounds of the triple incretin receptor co activation dose response curve before progressing through the 30mg, 40mg, 50mg, and 60mg concentration points available across CSD’s complete GLP-3 RTA range.
The triple receptor mechanism remains consistent across all GLP-3 RTA presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic and bone turnover research dimensions. Glucagon receptor co activation adds hepatic glucose output regulation, thermogenic energy expenditure stimulation, and lipolytic activity, producing a synergistic metabolic response that distinguishes triple incretin agonism from the dual GIP/GLP-1 mechanism of CSD’s GLP-2 TZ and GLP-2 TRZ listings and the pure GLP-1 selectivity of the Semaglutide pen.
Hudson Science formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and Hudson Science’s GLP-3 RTA 20mg meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
Next to a miracle. If you really want to change your life, this is it. I can’t tell you how happy and blessed I feel to have found this site. Thank you so much. I love you guys!!
★★★★★RandyVerified buyer2026-08-03
Down 25lbs great stuff. Definitely recommend for anyone curious.
GLP-3 RTA contains 20mg of RTA, an investigational peptide commonly described as a Triple G receptor agonist. RTA activates three metabolic hormone receptors: GIP, GLP-1, and glucagon within a single molecule. Research has focused on body weight regulation, appetite signaling, glucose metabolism, insulin sensitivity, energy expenditure, lipid metabolism, and broader cardiometabolic function.
RTA is called Triple G because it simultaneously activates the glucose dependent insulinotropic polypeptide (GIP), glucagon like peptide 1 (GLP-1), and glucagon receptors. GIP and GLP-1 are incretin pathways involved in glucose regulation, insulin response, and appetite signaling, while glucagon receptor activity contributes additional effects involving hepatic metabolism and energy expenditure. This three receptor profile distinguishes RTA from single and dual incretin agonists.
Semaglutide primarily activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. RTA activates GIP, GLP-1, and glucagon receptors simultaneously. The additional glucagon receptor activity gives RTA a distinct research profile involving energy expenditure, lipid metabolism, hepatic metabolism, appetite regulation, and glucose control.
RTA is being investigated extensively in clinical research involving obesity, body weight regulation, type 2 diabetes, glycemic control, and cardiometabolic health. Research has also examined changes in liver fat, lipid metabolism, appetite, insulin sensitivity, and other metabolic markers. Its triple GIP, GLP-1, and glucagon receptor mechanism is designed to combine complementary pathways involved in energy intake, glucose regulation, and energy expenditure.
Yes! This batch is HPLC tested to verify RTA identity and content accuracy at 20mg per vial. A certificate of analysis is available.
![GLP-3 RTA [Triple G] - 20mg](https://www.canadasteroiddepot.is/wp-content/uploads/2025/10/HUD-GLP3-20-300x300-1.webp)
![GLP-3 RTA [Triple G] - 10mg](https://www.canadasteroiddepot.is/wp-content/uploads/2024/10/HUD-GLP3-10-300x300.webp)
![GLP-3 RTA [Triple G] - 20mg](https://www.canadasteroiddepot.is/wp-content/uploads/2025/10/HUD-GLP3-20-300x300-1-100x100.webp)